ClinicalTrials.gg
RecruitingNCT03826992Updated Feb 18, 2026

Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia

A Phase 1 interventional study of Vyxeos and Venetoclax in Leukemia, sponsored by Children's Hospital Medical Center, Cincinnati. Recruiting at 1 site in United States. Open to participants aged 1 Year to 39 Years. Per ClinicalTrials.gov, last updated 2026-02-18.

Sponsored by Children's Hospital Medical Center, Cincinnati · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2018; still recruiting 7 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
21
Allocation
Not applicable
Ages
1 Year to 39 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 29 studies testing venetoclax in Leukemia — 16 open to participants now, 20 under way, 3 of them phase 3. venetoclax · Leukemia.

Planned enrollment
22nd of 29
21 · median 42
Started
2018
with 2 others
Phase 1
7 of 29
5 open now
Primary completion
2027-01
later than 6 of 19 live
Registered
8th of 29
by date
Lead sponsor
1 of 29
Children's Hospital Medical Center, Cincinnati

Among the 29 studies testing venetoclax in Leukemia, this one is the 22nd largest by planned enrollment, is one of 3 that started in 2018, is one of 7 in phase 1, reaches primary completion later than 6 of the 19 other live ones, and was the 8th registered.

Leukemia

2,382 studies on the registry are indexed under Leukemia; 252 are open to participants now.

Browse Leukemia studies →

Open to participants now

16 of the 29 studies testing venetoclax in Leukemia are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About venetoclax

venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 206 Leukemia studies recruiting now, 111 (54%) set no upper age limit and 74 (36%) stop at 75 or younger; 85 take children under 18; 24 take healthy volunteers.

This study: 1 Year to 39 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing venetoclax in Leukemia, or all of them as a file.
02

Study summary

This study evaluates the safety and tolerability of combining venetoclax with Vyxeos (CPX-351) in pediatric and young adult patients with acute leukemia that has come back or not responded to treatment.

Read the detailed description

This is a single-institution Phase I pilot study designed to test the safety and tolerability of combining venetoclax with Vyxeos (CPX-351, cytarabine and daunorubicin liposome) for the treatment of relapsed/refractory acute leukemia in young patients. Subjects will receive a single course of study therapy consisting of daily, oral or crushed venetoclax at an assigned dose level with a 3-day ramp-up to target dose and Vyxeos administered intravenously at the established dose on Days 1, 3, and 5. In addition to safety and tolerability, the overall response rate to these therapies will be estimated. Pharmacokinetic (PK) analysis will also be conducted to define the drug clearance of venetoclax in this combination.

03

Conditions studied

  • Leukemia

Keywords

  • relapsed
  • refractory
  • Vyxeos
  • Venetoclax
  • acute myeloid leukemia
  • acute myeloid leukemia, childhood
  • mixed-lineage leukemia (MLL)
  • AML
  • CPX-351
  • Venclexta
  • Histone-lysine N-methyltransferase 2A (KmT2A)
04

Who can participate

Ages eligible
1 Year to 39 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ages 1 Year to 39 Years
  • Diagnosis of one of the following:

    • Acute myeloid leukemia (AML), any subtype except

      • Patients with acute promyelocytic leukemia (APML) are NOT eligible
      • Patients with ML-DS are NOT eligible
    • Myeloid sarcoma
    • Acute leukemia of ambiguous lineage (ALAL)

      • Acute undifferentiated leukemia (AUL)
      • T/myeloid mixed phenotype acute leukemia (MPAL)
      • B/myeloid MPAL
      • MPAL with KMT2A-rearrangement MPAL with t (9;22) are NOT eligible
    • T-cell acute lymphoblastic leukemia (T ALL)
    • Early thymocyte precursor (ETP) ALL
    • KMT2A-rearranged ALL
  • Disease Status

    • AML, MPA, and AUL
    • Untreated therapy related AML
    • Relapsed/Refractory KMT2A-rearranged ALL, T-cell ALL, ETEP ALL
  • /Lanksy performance level score of greater than or equal to 50 percent.
  • Prior therapy requirements

    • Fully recovered from acute toxicities of Hematopoietic Stem Cell Transplant () or Anthracycline Exposure
    • 14 days must have elapsed since the completion of systemic cytotoxic therapy other than hydroxyurea, decitabine or azacitidine
    • 2 weeks must have elapsed for local palliative radiotherapy (RT); 6 months must have elapsed if prior craniospinal RT or if 50% radiation of pelvis, and at least 6 weeks must have elapsed if other substantial bone marrow radiation
  • Adequate renal, liver, cardiac, and central nervous system (CNS) function

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of one of the following:

    • Myeloid Leukemia associated with Down Syndrome (ML-DS)
    • Acute Promyelocytic Leukemia (APML)
    • Acute leukemia with CNS status 3 involvement
    • Philadelphia chromosome t(9;22) positive leukemia (Ph+ ALL, AML, MPAL, or AUL)
    • Fanconi Anemia, Shwachman-Diamond syndrome, or any other bone marrow failure syndrome or DNA repair disorder
    • Wilson's Disease or other copper-metabolism disorder
  • Pregnant or breastfeeding
  • Uncontrolled infection
  • Received greater than 13.6 Gray (Gy) prior radiation to the mediastinum
  • Receipt of growth factors within 7 days prior to enrollment
  • Currently receiving another drug
  • Currently receiving anti-cancer agents (with the exception of intrathecal (IT) agents or hydroxyurea)
  • Unable to comply with the safety monitoring requirements of the study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
21 participants (estimated)

Study arms

  • Experimental
    Venetoclax and Vyxeos combination

    Venetoclax will be given orally on Days per the assigned dose level. A single course consisting of 3 doses of Vyxeos and 7-21 doses of venetoclax depending on the assigned dose level will be administered to participants in this study. Vyxeos will be administered by central venous catheter over 90 minutes on Day 1, 3, and 5. Venetoclax is given daily by mouth per assigned dose level.

    Drug: Vyxeos · Drug: Venetoclax

Interventions

  • DrugCPX-351Studies of CPX-351CPX-351 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Vyxeos Dose: daunorubicin 44 mg/m2 and cytarabine 100 mg/m2 administered via intravenous infusion over 90 minutes on Days 1, 3, and 5.

    Also known as: cytarabine and daunorubicin liposome, CPX-351

  • Venetoclax Dose: 1. Dose Level 0 - weight based daily dosing for 21 days 2. Dose Level -1 - weight based daily dosing for 14 days 3. Dose Level -2- weight based daily dosing for 10 days 4. Dose Level -3- weight based daily dosing for 7 days

    Also known as: Venclexta

06

What researchers measure

Primary outcomes

  1. Feasibility of combining venetoclax and Vyxeos (dose limiting toxicities)

    If 2 or more participants have dose limiting toxicities at a given dose level, the maximum tolerated dose will have been exceeded.

    Time frame: 28 days

  2. Treatment related toxicities

    Number of related adverse events

    Time frame: 60 days

Secondary outcomes

  1. Disease response

    Estimate of overall response rate (ORR) defined as (CR/CRi/CRp).

    Time frame: 42 days

  2. Cancer therapeutics-related cardiac dysfunction (CTRCD) in patients who have previously received anthracyclines

    Measured by echocardiogram (ECHO)

    Time frame: 60 days

07

Study locations

1 of 1 sites recruiting
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
    Recruiting
    • Site Public Contact · Contactcancer@cchmc.org · 513-636-2799
    • John Perentesis, MD · Principal investigator
    • Laura Agresta, MD · Sub investigator
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2018 (actual). Primary completion is estimated for Jan 2027, 97 months after the start.

Of 112 non-industry phase 1 interventional studies under Leukemia, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 88. This study's planned 97 months is above that.

Counting every sponsor, half of 162 studies reached it within 53 months; a quarter within 34 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2019
First posted
Feb 1, 2019
StartActual
Dec 27, 2018
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2028
Last update
Feb 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03826992
Responsible party
Sponsor
First posted
Feb 1, 2019
Start date
Dec 27, 2018
Primary completion
Jan 2027 (estimated)
Completion
Jan 2028 (estimated)
Last update
Feb 18, 2026

Study contacts

Site Pulblic Contact
Contact
cancer@cchmc.org
513-636-2799
John Perentesis, MD
principal investigator · Children's Hospital Medical Center, Cincinnati

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: CPX-351 · Venetoclax

Start the discussion